Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Unternehmen & Branche
| Name | Eton Pharmaceuticals, Inc. |
|---|---|
| Ticker | ETON |
| CIK | 0001710340 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 29772l108 |
|---|---|
| ISIN | US29772L1089 |
| Typ | Common Stock |
| Marktkapitalisierung | 656,7 Mio. USD |
| Beta | 0,97 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 79,950,000 | -4,601,000 | 92,114,000 | 26,154,000 | |
| 2025-09-30 | 10-Q | 22,459,000 | -1,927,000 | -0.07 | 104,510,000 | 23,126,000 |
| 2025-06-30 | 10-Q | 18,928,000 | -2,585,000 | 101,676,000 | 23,961,000 | |
| 2025-03-31 | 10-Q | 17,282,000 | -1,572,000 | 84,032,000 | 24,450,000 | |
| 2024-12-31 | 10-K | 39,011,000 | -3,823,000 | 76,123,000 | 24,428,000 | |
| 2024-09-30 | 10-Q | 10,324,000 | 627,000 | 0.02 | 35,841,000 | 15,981,000 |
| 2024-06-30 | 10-Q | 9,074,000 | -3,041,000 | -0.12 | 31,823,000 | 13,462,000 |
| 2024-03-31 | 10-Q | 7,966,000 | -811,000 | -0.03 | 30,794,000 | 15,494,000 |
| 2023-12-31 | 10-K | 31,642,000 | -936,000 | 31,740,000 | 15,477,000 | |
| 2023-09-30 | 10-Q | 7,028,000 | -579,000 | -0.02 | 31,526,000 | 16,892,000 |
| 2023-06-30 | 10-Q | 11,997,000 | 4,559,000 | 0.18 | 30,932,000 | 16,725,000 |
| 2023-03-31 | 10-Q | 5,304,000 | -2,660,000 | -0.10 | 23,928,000 | 11,241,000 |
| 2022-12-31 | 10-K | 21,251,000 | -9,021,000 | 25,030,000 | 13,078,000 | |
| 2022-09-30 | 10-Q | 3,219,000 | -3,045,000 | -0.12 | 21,520,000 | 11,181,000 |
| 2022-06-30 | 10-Q | 7,358,000 | -1,558,000 | -0.06 | 23,046,000 | 13,242,000 |
| 2022-03-31 | 10-Q | 2,176,000 | -5,330,000 | -0.21 | 23,196,000 | 13,383,000 |
| 2021-12-31 | 10-K | 21,832,000 | -1,955,000 | 27,465,000 | 17,630,000 | |
| 2021-09-30 | 10-Q | 775,000 | -6,094,000 | -0.24 | 26,606,000 | 15,660,000 |
| 2021-06-30 | 10-Q | 3,067,000 | -2,016,000 | -0.08 | 29,906,000 | 20,736,000 |
| 2021-03-31 | 10-Q | 11,897,000 | 5,116,000 | 0.19 | 31,186,000 | 21,555,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.